ALFA Finder| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 142.1 | 125.5 | 121.7 |
| Other income | 6.1 | 7.8 | 5.3 |
| Total income | 148.2 | 133.4 | 127.0 |
| Profit before exceptional items & tax | 36.0 | 32.3 | 22.0 |
| Profit before tax | 36.0 | 32.3 | 22.0 |
| Net profit | 26.7 | 24.8 | 16.6 |
| Operating margin | 24.3% | 24.2% | 17.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +60.80% |
|---|---|
| Net profit, quarter on quarter | +7.70% |
| Revenue, year on year | +16.80% |
| Operating profit, year on year | +79.00% |
| Operating profit, quarter on quarter | +22.00% |
BSE results filing, NSE: SYNCOMF. Figures extracted from the filing.
Syncom Formulation (India) Ltd: key numbers
- Share price
- ₹20.29
- Market cap
- ₹1,907 Cr
- Revenue (annual)
- ₹489.2 Cr
- Net profit (annual)
- ₹76.44 Cr
- P/E (TTM)
- 19.9×Sector 43.7×
- Promoter holding
- 50.57%+0.00% QoQ
- FII holding
- 2.23%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Syncom Formulation (India) Ltd
All →Syncom Formulation (India) Board Meeting Date
Syncom Formulations (India) Limited has scheduled a board meeting for November 13, 2026. The board will consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026.
Syncom Formulation (India) Other Announcement
Syncom Formulations (India) Limited filed its quarterly shareholding pattern as per SEBI Regulation 31(1)(b) for the period ended September 30, 2026.
Syncom Formulation (India) Dividend
Syncom Formulations (India) Ltd shareholders approved a final dividend of Rs. 0.10 per equity share at the 38th AGM, totaling Rs. 9.40 Crore.
- Value
- ₹9.40 Cr
Syncom Formulation (India) Management Change
Syncom Formulations (India) Limited announced the appointments of Rahul Vijay Bankda as Managing Director and Rinki Ankit Bankda as Whole Time Director. Ruchi Jindal was reappointed.
Syncom Formulation (India) Annual General Meeting
Syncom Formulations (India) Limited held its 38th Annual General Meeting on September 30, 2026, via video conferencing to transact various ordinary and special business items.
Syncom Formulation (India) Other Announcement
Syncom Formulations' promoters have voluntarily waived their right to the proposed final dividend of ₹0.10 per share. This waiver reduces total dividend payout obligations.
- Value
- ₹4.75 Cr